Sequel Med Tech announced at the American Diabetes Association’s 85th Scientific Sessions in Chicago that it is preparing to launch its twiist system in July. Dr. Joanna Mitri, Sequel’s Chief Medical Officer, provided the update during a Product Theater session at the ADA event, stating that the automated insulin delivery system is scheduled for launch on July 7. This marks a slight delay from the company’s earlier projection in March, when it anticipated a second-quarter rollout.
The twiist system is built upon proprietary drug delivery technology developed by DEKA R&D. Dean Kamen, co-founder of Sequel and founder of DEKA, who previously pioneered the first wearable insulin pump, described twiist as the “next generation of insulin delivery” when discussing the system last year. Sequel secured FDA clearance for twiist in March 2024.
At the core of the twiist system is its integration with the twiist Loop algorithm, which enables precise measurement of insulin volume delivered with each microdose. Utilizing sound wave technology, the system accurately monitors every pulse of insulin, enhancing dosing precision and offering detailed insight into the exact amount of insulin administered per dose. This level of precision supports highly individualized dosing tailored to each patient’s specific needs.
The twiist system incorporates Sequel’s iiSure technology, featuring four safety checkpoints that ensure accurate insulin delivery and rapidly notify users of any blockages. The system is FDA-cleared for individuals aged six and older with type 1 diabetes, providing a more personalized and responsive approach to diabetes management.
In March, Sequel also announced a partnership with Abbott to integrate Abbott’s Libre continuous glucose monitor (CGM) as the first CGM platform compatible with twiist. Additionally, the company has reached agreements to integrate the system with Abbott’s forthcoming dual glucose-ketone sensor and with Senseonics’ Eversense 365, a year-long implantable CGM, broadening the system’s connectivity and enhancing patient monitoring options.